Health & Medicine

• Policy & Insight
• Health & Medicine

Opinion: ‘Widening health inequalities in England should be a wake-up call for the Government’

Life expectancy has failed to increase for a decade across England for the first time in 100 years. And cuts to stop smoking services are part of the problem. Life expectancy has failed to increase for a decade across England for the first time in 100 years. And cuts to stop smoking services are part of the problem.

25 February 2020

• Health & Medicine

England off track to meet government's 2030 smoke-free target

England will fail to be smoke-free by 2030 if current smoking trends continue, according to a report released today from Cancer Research UK. England will fail to be smoke-free by 2030 if current smoking trends continue, according to a report released today from Cancer Research UK.

25 February 2020

• Health & Medicine

Kidney cancer drug gets initial ‘no’ for the NHS in England

A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England

17 February 2020

• Health & Medicine

Two skin cancer treatments get the green light for NHS Scotland

An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC).  An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC). 

12 February 2020

• Health & Medicine

Targeted lung cancer treatment gets initial ‘no’ for NHS in England

Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua).  Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua). 

4 February 2020

• Health & Medicine

Leukaemia and head and neck cancer drugs not approved for NHS use in England

Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England. Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.

23 January 2020

• Health & Medicine

Hormone therapy now available for newly diagnosed prostate cancer in Scotland 

A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.   A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.  

20 January 2020

• Health & Medicine

New breed of targeted cancer drug gets initial ‘no’ for NHS in England  

A targeted drug, larotrectinib (Vitrakvi), will not be made an option for adults and children whose tumours test positive for a specific genetic change. A targeted drug, larotrectinib (Vitrakvi), will not be made an option for adults and children whose tumours test positive for a specific genetic change.

15 January 2020

• Health & Medicine

Lung cancer immunotherapy gets initial ‘no’ for NHS in England

An immunotherapy and chemotherapy combo has been rejected for some adults with small cell lung cancer on the NHS in England. An immunotherapy and chemotherapy combo has been rejected for some adults with small cell lung cancer on the NHS in England.

8 January 2020

• Health & Medicine

Targeted ovarian cancer drug made available to more people on NHS in England

NICE has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England. NICE has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England.

11 December 2019

• Health & Medicine

Targeted ovarian cancer drug made more widely available on the NHS in Scotland

A targeted cancer drug has been approved for use on the NHS in Scotland for patients with newly diagnosed ovarian cancer that’s responded to chemotherapy. A targeted cancer drug has been approved for use on the NHS in Scotland for patients with newly diagnosed ovarian cancer that’s responded to chemotherapy.

9 December 2019

• Health & Medicine

Bladder cancer treatment rejected for routine use on NHS in England


A treatment option for some people with bladder cancer, currently available through the CDF has been given an initial ‘no’ for routine use in England. 
A treatment option for some people with bladder cancer, currently available through the CDF has been given an initial ‘no’ for routine use in England.

26 November 2019